An alternative method to analyse the biomarker‐strategy design
An alternative method to analyse the biomarker‐strategy design
Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identification of subgroups of patients responding well to a treatment. One currently used clinical trial design incorporating a predictive biomarker is the so‐called biomarker strategy design (or marker‐based strategy design). Conventionally, the results from this design are …